Thermo Fisher Scientific Inc. (NYSE:TMO) Receives Average Rating of "Moderate Buy" from Brokerages

Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twenty-two analysts that are currently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $589.3810.

Several analysts recently commented on the company. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research report on Friday, July 11th. UBS Group raised their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research report on Thursday, July 24th. Barclays increased their price target on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research note on Thursday, July 24th. Raymond James Financial reaffirmed an "outperform" rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Finally, Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the company an "outperform" rating in a research note on Tuesday, September 2nd.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded down $5.38 on Tuesday, reaching $477.03. 1,442,085 shares of the company were exchanged, compared to its average volume of 1,608,466. Thermo Fisher Scientific has a 1-year low of $385.46 and a 1-year high of $623.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm has a market cap of $180.13 billion, a price-to-earnings ratio of 27.59, a P/E/G ratio of 2.58 and a beta of 0.75. The company's 50-day moving average is $463.59 and its two-hundred day moving average is $452.20.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same period last year, the firm earned $5.37 EPS. The firm's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts expect that Thermo Fisher Scientific will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several large investors have recently modified their holdings of the stock. NWF Advisory Services Inc. bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth $377,000. Reynders McVeigh Capital Management LLC boosted its stake in shares of Thermo Fisher Scientific by 0.5% during the 2nd quarter. Reynders McVeigh Capital Management LLC now owns 9,710 shares of the medical research company's stock worth $3,937,000 after acquiring an additional 45 shares in the last quarter. SevenBridge Financial Group LLC boosted its stake in shares of Thermo Fisher Scientific by 38.3% during the 2nd quarter. SevenBridge Financial Group LLC now owns 4,955 shares of the medical research company's stock worth $2,009,000 after acquiring an additional 1,371 shares in the last quarter. Osaic Holdings Inc. boosted its stake in shares of Thermo Fisher Scientific by 35.7% during the 2nd quarter. Osaic Holdings Inc. now owns 67,715 shares of the medical research company's stock worth $28,572,000 after acquiring an additional 17,806 shares in the last quarter. Finally, American Trust boosted its position in shares of Thermo Fisher Scientific by 1.7% in the second quarter. American Trust now owns 5,663 shares of the medical research company's stock worth $2,296,000 after buying an additional 93 shares during the period. 89.23% of the stock is owned by institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.